Detailed sections on cell wall inhibitors, protein inhibitors, and cancer chemotherapy.
The 2023 revision of Annex 1 for sterile products mandates a . The Dhshan framework provides a dedicated CCS template, bridging the gap between environmental monitoring and risk assessment. pharma guide dhshan pdf